- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04765345
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F (RUSH1F)
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher
Study Overview
Status
Detailed Description
This natural history study of patients with PCDH15 disease-causing variants will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to PCDH15 disease-causing variants. Together these approaches are expected to have an impact on understanding PCDH15 related retinal degeneration, developing experimental treatment protocols, and assessing their effectiveness.
The goals and expected impact of this natural history study are to:
- Describe the natural history of retinal degeneration in patients with biallelic disease-causing variants in the PCDH15 gene
- Contribute to the identification of sensitive structural and functional outcome measures to use for future multicenter clinical trials in PCDH15 related retinal degeneration
- Contribute to the identification of populations for future clinical trials of investigative treatments for PCDH15 related retinal degeneration
Study Objectives
The primary objectives of the natural history study are to:
- Characterize the natural history of retinal degeneration associated with biallelic pathogenic mutations in the PCDH15gene over 4 years, as measured using functional, structural, and patient-reported outcome measures
- Explore whether structural outcome measures can be validated as surrogates for functional outcomes in individuals with biallelic pathogenic mutations in the PCDH15 gene
- Explore possible risk factors (genotype, phenotype, environmental, and comorbidities) for progression of the outcome measures at 4 years in individuals with biallelic pathogenic mutations in the PCDH15 gene
- Explore variability and symmetry of left and right eye outcomes over 4 years in individuals with biallelic pathogenic mutations in the PCDH15 gene
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Coordinating Center
- Phone Number: 8139758690
- Email: ffb@jaeb.org
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Hospital For Sick Children
-
-
-
-
-
Paris, France
- CHNO des Quinze-Vingts
-
-
-
-
-
Tübingen, Germany
- University of Tubingen
-
-
-
-
-
Jerusalem, Israel
- Haddassah Medical Center
-
-
-
-
-
Nijmegen, Netherlands
- Radboud University
-
-
-
-
-
Basel, Switzerland, 4031
- University Hospital Basel
-
-
-
-
California
-
San Francisco, California, United States, 94143-0344
- University of California, San Francisco
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- The Johns Hopkins Wilmer Eye Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University, Duke Eye Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Participants must meet all the following inclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.
- Willing to participate in the study and able to communicate consent during the consent process
- Ability to return for all study visits over 48 months
- Age ≥ 8 years
- Not planning to enroll in an experimental clinical trial for the treatment of PCDH15 for the duration of this study
Must meet one of the Genetic Screening Criteria, defined below:
- Screening Group A: At least 2 disease-causing variants in the PCDH15 gene which are homozygous or heterozygous in trans, based on a report from a clinically certified lab (or a report from a research lab that has been pre- approved by the Genetics Committee)
- Screening Group B: Only 1 disease-causing variant in the PCDH15 gene, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)
- Screening Group C: At least 2 disease-causing variants in the PCDH15 gene which are unknown phase, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)
Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify if there is at least 1 disease-causing variant(s) on the PCDH15 gene.
Ocular Inclusion Criteria
Both eyes must meet all the following at the Screening Visit for a participant to be eligible to enroll into the genetic screening phase.
- Clinical diagnosis of retinal dystrophy
- Clear ocular media and adequate pupil dilation to permit good quality photographic imaging
Exclusion Criteria:
Participants must not meet any of the following exclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.
- Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PCDH15
- Expected to enter experimental treatment trial at any time during this study
- History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)
Note: Pregnant women are not being specifically excluded from participation.
Ocular Exclusion Criteria
If either eye has any of the following at the Screening Visit, the participant is not eligible to enroll into the genetic screening phase.
- Current vitreous hemorrhage
- Current or any history of tractional or rhegmatogenous retinal detachment
- Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
- History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
- Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)
- Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
- History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:
- Any use of ocular stem cell or gene therapy
- Any treatment with ocriplasmin
- Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)
- Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)
- Treatment with Ozurdex (dexamethasone), Iluvien or Yutiq (fluocinolone acetonide) intravitreal implant
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Vision Cohort 1
~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field. The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date. |
Vision Cohort 2
~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field). The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visual Field Sensitivity
Time Frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
|
measured by static perimetry with quantitative, topographic analysis (Hill of Vision) and assessed by a central reading center
|
Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
|
Change in Best Corrected Visual Acuity
Time Frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
|
Early Treatment of Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity (BCVA) letter score as measured on the Electronic Visual Acuity (EVA) system or ETDRS charts.
Letter score range values=0-100 (with higher values = better and lower values = worse.)
Berkeley Rudimentary Vision Test (BRVT) will be used for patients unable to see letters.
|
Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
|
Change in Mean Retinal Sensitivity
Time Frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
|
Measured by fundus-guided microperimetry (MP) and assessed by a central reading center at selected sites with requisite equipment.
|
Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
|
Change in Full-field Retinal Sensitivity
Time Frame: Baseline, 12Month, 24Month, 36Month, and 48Month
|
Measured by full-field stimulus threshold (FST) testing to blue, white and red stimuli.
|
Baseline, 12Month, 24Month, 36Month, and 48Month
|
Change in Best Corrected Low Luminance Visual Acuity (LLVA)
Time Frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
|
Measured by Letter Score.
Letter score range values=0-100 (with higher values = better and lower values = worse.)
|
Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
|
Change in Contrast Sensitivity Function (CSF)
Time Frame: Baseline, 12Month, 24Month, 36Month, and 48Month
|
Measured by the CSV-1000E VectorVision chart
|
Baseline, 12Month, 24Month, 36Month, and 48Month
|
Change in ellipsoid zone (EZ) area
Time Frame: Baseline, 12Month, 24Month, 36Month, and 48Month
|
Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a central reading center.
|
Baseline, 12Month, 24Month, 36Month, and 48Month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore qualitative categorization of Fundus Autofluorescence (FAF) pattern
Time Frame: Baseline, 12Month, 24Month, 36Month, and 48Month
|
Assessed by a central reading center.
|
Baseline, 12Month, 24Month, 36Month, and 48Month
|
Explore quantitative measures of FAF
Time Frame: Baseline, 12Month, 24Month, 36Month, and 48Month
|
Assessed by a central reading center.
|
Baseline, 12Month, 24Month, 36Month, and 48Month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Outcomes (Adults 18 years or older)
Time Frame: Baseline, 24Month, and 48Month
|
Measured by Michigan Retinal Degeneration Questionnaire (MRDQ) MRDQ - consists of 59 items using categories: : ''None: I do not have trouble with this,'' ''A little difficulty: I notice a problem, but I do not struggle,'' ''Moderate difficulty: I struggle but I can still do this,'' ''Extreme difficulty : I struggle a lot and sometimes I cannot do this,'' and ''N/A for non-vision reasons: I do not do this.'
|
Baseline, 24Month, and 48Month
|
Patient Reported Outcomes (Adults 18 years or older)
Time Frame: Baseline, 24Month, and 48Month
|
Measured by Patient-Reported Outcomes Measurement Information System (PROMIS®-29)
|
Baseline, 24Month, and 48Month
|
Patient Reported Outcomes (less than 18 years):
Time Frame: Baseline, 24Month, and 48Month
|
L. V. Prasad-Functional Vision Questionnaire (LVP-FVQ II) The LVP-FVQ II consists of 23 items using 3 categories: 1, no difficulty; 2, some difficulty; 3, a lot of difficulty
|
Baseline, 24Month, and 48Month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Katarina Stingl, MD, University Hospital Tuebingen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RUSH1F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Degeneration
-
Seoul National University Bundang HospitalUnknownAge-Related Macular Degeneration | Retinal DrusenKorea, Republic of
-
University of LuebeckCompletedAge-Related Macular Degeneration | Retinal FunctionGermany
-
Stanford UniversityBascom Palmer Eye InstituteCompletedMacular Degeneration | Retinal DrusenUnited States
-
Guardion Health Sciences, Inc.Western University of Health Sciences; Eye Clinic of AustinCompletedMacular Degeneration | Age-related Macular Degeneration | Retinal DrusenUnited States
-
Benha UniversityRecruitingMacula Lutea DegenerationUnited Arab Emirates
-
Sorlandet Hospital HFActive, not recruitingWet Macular DegenerationNorway
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationJapan
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationItaly
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance